Prevalence of thyroid disorders in hepatitis C virus positive patients on interferon and antiviral therapy

Goyal, Gitanjali; Panag, Kmds; Garg, Ravinder

doi:10.4103/2229-516x.192587

Cited by 8 publications

(7 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a similar study, Goyal et al (2016) [7]. It can be said that results of previous studies are comparable with results of this study as well.…”

Section: Discussionsupporting

confidence: 89%

“…There is no or weak association between severity of the disease and response to therapy with IFN-induced thyroid dysfunction. 13 (26%) of the patients were found to develop hypothyroidism, and 1 (2%) patient developed hyperthyroidism in the course of 12 weeks therapy [13]. It was observed that female patients (10.4%) had relatively higher rate of developing hypothyroidism than male patients.…”

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

Frequency of Hypothyroidism in Patients with Hepatitis C on Standard Interferon Therapy

Chachar¹,

Anjum²,

Fatima³

et al. 2017

Natl. j. health sci.

View full text Add to dashboard Cite

Introduction: Hepatitis C virus (HCV) infection is an emerging public health issue affecting young people in developing countries. It is the common cause of chronic liver disease which if untreated, leads to cirrhosis, hepatocellular carcinoma and ultimately liver transplantation. HCV infection is conventionally treated with Interferon-α (IFN-α) and anti-viral Ribavirin (RBV). Thyroid dysfunction is frequently encountered in patients having HCV and being treated with IFN-α and antiviral (RBV).Objective: To find out the incidence of thyroid dysfunction i.e., hypothyroidism in patients of HCV infection being treated with IFN-α and anti-viral (RBV). Material and Methods:250 patients having HCV infection were enrolled for the study. All patients were treated with 3 million units subcontinually 3 times per week and antiviral (RBV). Thyroid function tests were performed at the start of the treatment to have a baseline thyroid status and at the end of the treatment. Patients were considered to have hypothyroidism when thyroid stimulating hormone (TSH) was more than 4.0 mIU/L.Results: 47 (18.8%) patients had thyroid dysfunction after 3 months of the therapy. Out of these 47 patients, 36 (76.59%) had hypothyroidism and 11 (23.4%) had hyperthyroidism. It is evident that patients on IFN-α and antiviral therapy for HCV infection developed thyroid dysfunction particularly hypothyroidism that is more in females.

show abstract

“…In a similar study, Goyal et al (2016) [7]. It can be said that results of previous studies are comparable with results of this study as well.…”

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 95%

Frequency of Hypothyroidism in Patients with Hepatitis C on Standard Interferon Therapy

Chachar¹,

Anjum²,

Fatima³

et al. 2017

Natl. j. health sci.

View full text Add to dashboard Cite

show abstract

“…One study revealed that overt AITD occurred in about 5–10% of INF- α -treated patients [24]. A recent study has also found that 2% of patients developed hyperthyroidism in the HCV-positive patients during a 12-week course of INF- α antiviral therapy [25]. Therefore, studies have indicated that INF- α is one of the important immune factors that induce AITDs [26, 27].…”

Section: Discussionmentioning

confidence: 99%

IRF7 Gene Variations Confer Susceptibility to Autoimmune Thyroid Diseases and Graves’ Ophthalmopathy

Yao

Zhang

et al. 2019

International Journal of Endocrinology

View full text Add to dashboard Cite

The objective of this study was to investigate whether IRF7 polymorphisms are associated with autoimmune thyroid diseases (AITDs). We selected three single nucleotide polymorphisms (SNPs) of IRF7, namely, rs1061501, rs1131665, and rs1061502 for genotyping using PCR-based ligase detection reaction (LDR) method in a total of 1659 participants (592 with Graves' disease, 297 with Hashimoto's thyroiditis, and 770 healthy controls). Gene-disease and genotype-clinical phenotype associations were evaluated for the three SNPs. Our results showed that the AG genotype and the minor allele G frequency of rs1131665 and rs1061502 in AITD patients were both higher than those of the controls (rs1131665: AG genotype: P = 0.017, OR = 1.968; allele G: P = 0.018, OR = 1.946; rs1061502: AG genotype: P = 0.029, OR = 1.866; allele G: P = 0.031, OR = 1.847). Subgroup analysis also showed that the AG genotype and the minor allele G frequency of rs1131665 and rs1061502 in Graves' disease patients were both higher than those of the controls (rs1131665: AG genotype: P = 0.015, OR = 2.074; allele G: P = 0.016, OR = 2.048; rs1061502: AG genotype: P = 0.034, OR = 1.919; allele G: P = 0.035, OR = 1.898). Furthermore, the allele G frequency of rs1061501 was associated with Graves' ophthalmopathy (P = 0.035, OR = 1.396). No significant difference in IRF7 polymorphisms was found between Hashimoto's thyroiditis patients and controls. Our study has revealed for the first time that IRF7 is a susceptibility gene for AITD, especially for Graves' disease and Graves' ophthalmopathy.

show abstract

“…2 Existing literature suggest that thyroid dysfunction is the most common endocrine disorder that occurs in HCV infected patients and interferon (IFN) therapy has been associated with an increase in thyroid disorders. [3][4][5][6] This is the first-ever evidence to report thyroid dysfunction in two different groups of chronic hepatitis C (CHC) patients treated with two different direct-acting antiviral (DAA) drug combinations that are sofosbuvir + ribavirin + pegylated-IFN-α and sofosbuvir + ribavirin + daclatasvir.…”

Section: Introductionmentioning

confidence: 99%

Comparing the risk of hypothyroidism in HCV patients treated with different DAA drugs combinations (sofosbuvir + interferon + ribavirin and sofosbuvir + daclatasvir + ribavirin)

Wahid

Shami

Joiya

et al. 2020

Journal of Medical Virology

View full text Add to dashboard Cite

The recent development of direct‐acting antiviral (DAA) drugs has revolutionized the area of hepatitis C virus (HCV) therapeutics but the efficacy and clinical outcome of interferon (IFN)‐free therapy have not been extensively studied yet. We observed a dramatic increase in hypothyroidism among patients treated with sofosbuvir, IFN, and ribavirin. This is the first prospective study of the thyroid dysfunction in DAA drugs treated patients. This study compared the risk of hypothyroidism in two different groups of HCV patients treated with different DAA drugs regimens that were sofosbuvir + pegylated‐IFN‐α + ribavirin and sofosbuvir + daclatasvir + ribavirin. Our findings highlight the periodic screening of serum thyroid‐stimulating hormone and T4 levels in HCV infected patients during the treatment and posttreatment.

show abstract

Prevalence of thyroid disorders in hepatitis C virus positive patients on interferon and antiviral therapy

Cited by 8 publications

References 16 publications

Frequency of Hypothyroidism in Patients with Hepatitis C on Standard Interferon Therapy

Frequency of Hypothyroidism in Patients with Hepatitis C on Standard Interferon Therapy

IRF7 Gene Variations Confer Susceptibility to Autoimmune Thyroid Diseases and Graves’ Ophthalmopathy

Comparing the risk of hypothyroidism in HCV patients treated with different DAA drugs combinations (sofosbuvir + interferon + ribavirin and sofosbuvir + daclatasvir + ribavirin)

Contact Info

Product

Resources

About